Assignee
FELICITEX THERAPEUTICS INC
US·4 granted patents·4 pending applications·7 citations·filing 2013–2021
Top patents by PatentIndex Score
8 records- 0177US10322128B2Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitorsFELICITEX THERAPEUTICS INC·Filed 2017·Granted Jun 18, 2019·3 cites·20 claims
- 0274US10314843B2Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosisFELICITEX THERAPEUTICS INC·Filed 2017·Granted Jun 11, 2019·2 cites·20 claims
- 0371US11202779B2Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitorsFELICITEX THERAPEUTICS INC·Filed 2019·Granted Dec 21, 2021·1 cites·9 claims
- 0465US2022110940A1Combinations for the treatment of neoplasms using quiescent cell targeting with egfr inhibitorsFELICITEX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 0565US2022110941A1Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosisFELICITEX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 0657US10577365B2Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinasesFELICITEX THERAPEUTICS INC·Filed 2017·Granted Mar 3, 2020·1 cites·14 claims
- 0753US2019290651A1Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosisFELICITEX THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 0839US2015292032A1Treatment of cancer by targeting quiescent cancer cellsFELICITEX THERAPEUTICS INC·Filed 2013·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →